Ross and Catherine Kobayashi founded the Lung Transplant Equipment and Research Fund at the Calgary Foundation. Ross had an autoimmune disease called Idiopathic Pulmonary Fibrosis (IPF) which he dealt with for 6 years prior to transplantation. He had led an active life having summited Kilimanjaro 2 years prior to developing IPF. Ross received EVLP treated lungs in February 2017. His donor lungs were supported for 4 hours prior to transplantation.
For 25 years Ross owned and operated an energy advisory firm specializing in asset and corporate divestments.
This Fund at the Calgary Foundation is a Donor Advised Flow Through Fund. Cost Recovery is 1% against each gift and the remaining capital remains available to be granted to “qualified donees” for charitable purposes.
The Kobayashi’s have established a goal to attract $1 million. They personally seeded the Fund with an initial capital contribution of $100 thousand. As $$ are contributed and priority projects/research opportunities may be presented, the Kobayashis as the Fund Founders would make grant recommendations to advance proceeds for such charitable purposes. Advances in healthcare through equipment (such as EVLP’s) and related research would usually qualify as charitable purpose and the UofA would be an eligible qualified donee.
By example only, the University of Alberta’s Faculty of Medicine and Dentistry has identified transplants as a priority. More information is available at: http://www.albertatransplantinstitute.ualberta.ca/